John Mantsch

Corporate Officer/Principal at Marquette University

Consumer Services

Health Technology

Profile

John Mantsch is the founder of Promentis Pharmaceuticals, Inc. which was founded in 2007.
Currently, he is the Chairman of the Biomedical Sciences Department at Marquette University.
Dr. Mantsch completed his undergraduate degree at Allegheny College and his doctorate at Louisiana State University Shreveport.

John Mantsch active positions

Companies	Position	Start
Marquette University	Corporate Officer/Principal	-

All active positions of John Mantsch

Former positions of John Mantsch

Companies	Position	End
Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.	Founder	-

See the detail of John Mantsch's experience

Training of John Mantsch

Louisiana State University Shreveport	Doctorate Degree
Allegheny College	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John Mantsch's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Promentis Pharmaceuticals, Inc. Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.	Health Technology